SUMMARY Practicable methods are now available for whole population screening of neonates for cystic fibrosis. Although diagnosis and treatment of the disease from birth has not yet been unequivocally shown to improve prognosis, existing evidence suggests that this is likely. Further ethical reasons are proposed in support of neonatal diagnosis and early treatment. The development of tests for prenatal diagnosis and carrier detection is under active investigation, and raises ethical problems for heterozygotes and their medical advisers. The heavy financial and emotional burden this disease imposes on the patient and the family should not be underestimated when policy decisions are made.
It is possible to screen all newborn infants for cystic fibrosis (CF), the most common serious inherited disorder in European children. Whether population screening for any disease should be undertaken on a national scale depends on criteria which were summarised by Wilson and Jungnerl for the World Health Organisation in 1968. They proposed that screening is justified if (1) a disease is an important health problem for the individual and the community; (2) its natural history is known; (3) it has a latent or early symptomatic state; (4) it can be identified by a suitable screening test; (5) the facilities for definitive diagnosis and treatment are available and the treatment policy agreed; (6) the natural history of the disease is favourably modified by early, acceptable treatment; and (7) the exercise is cost-effective.
In an earlier review, Brimblecombe and Chamberlain2 considered that these criteria were not met in the case of cystic fibrosis. 
